Navigation Links
Semafore to Present at BIO CEO & Investor Conference
Date:2/8/2008

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marsha
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology ... Therabron Therapeutics , Inc. The new name is ... of structure in the lungs similar to branches on ... novel protein therapeutics for the treatment of respiratory diseases. ... the name to mark the company's escalation into the ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... exhibit to open Thursday , Madison, Wis. ... exhibit on advances in nanotechnology, run by the university and ... p.m. on December 16 during a campus open house, with ... science fiction as the manufacture of tiny robots, has led ...
... opening passages of Alice in Wonderland , you should. ... accurate description of most modern IT projects. , ,The business-like ... always just out of reach around the next turn of ... dialog. The falling, tumbling, almost hallucinogenic quality of a workload ...
... the highway reconstruction efforts continue their development in downtown Milwaukee, ... spent on a Web site that will update people on ... Marquette Interchange Project was established in September by the ... on the interchange, HNTP and CH2M Hill ...
Cached Biology Technology:Tech Digest: Nanotechnology, GE Healthcare, NovaMed, PhysioGenix 2The IT drug Just say no? 2The IT drug Just say no? 3$685,000 too much for construction Web site, critics say 2$685,000 too much for construction Web site, critics say 3
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... farmers worldwide to plant genetically modified (GM) cotton to ... several years by saving on pesticides have now been ... researchers at the American Agricultural Economics Association (AAEA) Annual ... that other pests are now attacking the GM cotton. ...
... after the end-Cretaceous mass extinction was much more chaotic ... shows that at certain times and places, plant and ... as they are today. The extinction took place 65.5 ... the beginning of the Cenozoic Era and the Paleocene ...
... five major food crops grown under carbon-dioxide levels ... bounty than those raised in earlier greenhouse and ... global food supplies could be at risk without ... are based on on-going open-air research at the ...
Cached Biology News:Bt cotton in China fails to reap profit after seven years 2Insect predation sheds light on food web recovery after the dinosaur extinction 2Insect predation sheds light on food web recovery after the dinosaur extinction 3Insect predation sheds light on food web recovery after the dinosaur extinction 4Food-crop yields in future greenhouse-gas conditions lower than expected 2